Family approach for estimating reference concentrations/doses for series of related organic chemicals

被引:20
作者
Barton, HA
Deisinger, PJ
English, JC
Gearhart, JM
Faber, WD
Tyler, TR
Banton, MI
Teeguarden, J
Andersen, ME
机构
[1] ICF Kaiser, KS Crump Grp, Res Triangle Pk, NC 27709 USA
[2] Eastman Kodak Co, Hlth & Environm Labs, Rochester, NY 14652 USA
[3] Union Carbide Corp, Hlth Safety & Environm Affairs Dept, Danbury, CT 06817 USA
[4] Shell Chem Co, Toxicol Hlth Safety & Environm, Houston, TX 77002 USA
关键词
hazard identification; dose-response assessment; butyl acetate; tissue dosimetry; mixtures; risk assessment; pharmacokinetics; reference dose (RfD); reference concentration (RfC);
D O I
10.1093/toxsci/54.1.251
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The family approach for related compounds can be used to evaluate hazard and estimate reference concentrations/doses using internal dose metrics for a group (family) of metabolically related compounds. This approach is based upon a simple four-step framework for organizing and evaluating toxicity data: 1) exposure, 2) tissue dosimetry, 3) mode of action, and 4) response, Expansion of the traditional exposure-response analysis has been increasingly incorporated into regulatory guidance for chemical risk assessment. The family approach represents an advancement in the planning and use of toxicity testing that is intended to facilitate the maximal use of toxicity data. The result is a methodology that makes toxicity testing and the development of acceptable exposure limits as efficient and effective as possible. An example is provided using butyl acetate and its metabolites (butanol, butyraldehyde, and butyrate), widely used chemicals produced synthetically by the industrial oxo process. A template pharmacokinetic model has been developed that comprises submodels for each compound linked in series. This preliminary model is being used to coordinately plan toxicity studies, pharmacokinetic studies, and analyses to obtain reference concentrations/ doses. Implementation of the family approach using pharmacokinetic modeling to obtain tissue dose metrics is described and its applications are evaluated.
引用
收藏
页码:251 / 261
页数:11
相关论文
共 46 条
[1]  
Aarstad K, 1985, Arch Toxicol Suppl, V8, P418
[2]   A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice [J].
Abbas, R ;
Fisher, JW .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 147 (01) :15-30
[3]  
Andersen ME, 1999, INHAL TOXICOL, V11, P899
[4]  
ANDERSON DK, 1991, RESTOR NEUROL NEUROS, V2, P309, DOI 10.3233/RNN-1991-245621
[5]  
[Anonymous], EPA600890066F US EPA
[6]   Harmonization: Developing consistent guidelines for applying mode of action and dosimetry information to cancer and noncancer risk assessment [J].
Barton, HA ;
Andersen, ME ;
Clewell, HJ .
HUMAN AND ECOLOGICAL RISK ASSESSMENT, 1998, 4 (01) :75-115
[7]   Dichloroacetate (DCA) dosimetry: interpreting DCA-induced liver cancer dose response and the potential for DCA to contribute to trichloroethylene-induced liver cancer [J].
Barton, HA ;
Bull, R ;
Schultz, I ;
Andersen, ME .
TOXICOLOGY LETTERS, 1999, 106 (01) :9-21
[8]  
BERNARD LG, 1996, N BUTYL ACETATE 13 W
[9]  
BISESI MS, 1994, PATTYS IND HYGIENE D, V2
[10]   Development of a physiologically based pharmacokinetic model for methyl tertiary-butyl ether and tertiary-butanol in male Fischer-344 rats [J].
Borghoff, SJ ;
Murphy, JE ;
Medinsky, MA .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1996, 30 (02) :264-275